Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

484
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
484
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.8K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.8K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
204
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

502
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
502
Skin Cancer01:30

Skin Cancer

4.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.6K
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

2.3K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.

JCI insight·2025
Same author

Characteristics of youth utilizing pediatric dermatology: A cross-sectional PEDSnet study.

Journal of the American Academy of Dermatology·2025
Same author

Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled Analysis.

Dermatitis : contact, atopic, occupational, drug·2025
Same author

Development and Validation of a Scale to Assess Epidermolysis Bullosa Simplex Severity.

JAMA dermatology·2025
Same author

Dupilumab Reduces Pruritus in Twins With Sjögren-Larsson Syndrome.

Pediatric dermatology·2025
Same author

Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.

Dermatology and therapy·2025

Related Experiment Video

Updated: Sep 18, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

New treatments in atopic dermatitis update.

Kennedy Gallagher1, Sofia Halperin-Goldstein2, Amy S Paller3

  • 1Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|June 25, 2025
PubMed
Summary

New therapies for atopic dermatitis, including topical nonsteroidals and biologics targeting IL-4/IL-13, offer improved options for patients of all ages. Ongoing research focuses on personalized treatments and long-term outcomes for this chronic skin condition.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.8K

Related Experiment Videos

Last Updated: Sep 18, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.8K

Area of Science:

  • Dermatology and Immunology
  • Pharmacology and Therapeutics

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant impact on quality of life.
  • Existing treatments for AD have limitations, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

  • To review the efficacy and safety of emerging topical and systemic therapies for atopic dermatitis in pediatric and adult populations.
  • To highlight recent advancements and future directions in AD treatment.

Main Methods:

  • Comprehensive literature search of peer-reviewed publications (PubMed), meeting abstracts, ClinicalTrials.gov, and industry press releases.
  • Evaluation of novel and emerging therapies, including nonsteroidal topicals, topical Janus kinase (JAK) inhibitors, biologics, and oral JAK inhibitors.
  • Assessment of therapies targeting specific pathways like IL-4/IL-13, IL-31, and OX40/OX40L.

Main Results:

  • Several new agents have received FDA approval, expanding therapeutic options for AD.
  • Approved nonsteroidal topical treatments include roflumilast and tapinarof.
  • Biologics targeting IL-4/IL-13 (dupilumab, tralokinumab, lebrikizumab) and IL-31 receptor (nemolizumab) are available for various age groups.
  • Oral JAK inhibitors (upadacitinib, abrocitinib) are approved for patients aged 12 and older in the US.

Conclusions:

  • Innovations in AD therapy signify a move towards personalized treatment approaches.
  • Investigational therapies like bacteriotherapy and agents targeting OX40/OX40L show promise.
  • Continued research is crucial for assessing long-term safety, efficacy, and optimizing patient outcomes.